Melanoma News and Research

Latest Melanoma News and Research

Sunbed users at a 20% increased relative risk of skin cancer

Of 63,942 new cases of cutaneous melanoma (a form of skin cancer) diagnosed each year in Europe an estimated 3,438 (5.4%) are related to sunbed use. Sunbed users are at a 20% increased relative risk of skin cancer compared with those who have never used a sunbed. This risk doubles if they start before the age of 35 and experts warn that “tougher actions” are needed to reduce this risk.

25 Jul 2012

New large animal model for human cancer studies

A naturally occurring line of immunodeficient pigs can support the growth of human tumors injected under their skin, offering a promising new large animal model for studying human cancers and testing new drugs and treatment strategies.

24 Jul 2012

Study identifies MDM4 protein as promising target for treatment of melanoma

A melanoma is a malignant form of skin cancer and is one of the most aggressive types of tumors there is. Treatment is particularly difficult, because melanomas are usually resistant against conventional chemotherapy treatments.

24 Jul 2012

UV induction of melanin is directly involved in melanoma formation

A new study conducted by GW School of Medicine and Health Sciences (SMHS) researchers Edward C. De Fabo, Ph.D., Frances P. Noonan, Ph.D., and Anastas Popratiloff, M.D., Ph.D., has been published in the journal Nature Communications. Their paper, entitled "Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment," was published in June 2012.

24 Jul 2012

Novel genomic sequencing method can help conduct in-depth analysis of single cells

Only by viewing a Georges Seurat painting at close range can you appreciate the hidden complexities of pointillism - small, distinct dots of color applied to form an image from a distance. Similarly, biologists and geneticists have long sought to analyze profiles of genes at the single cell level but technology limitations have only allowed a view from afar.

23 Jul 2012

Researchers identify six genes with driving mutations in melanoma

It's been a burning question in melanoma research: Tumor cells are full of ultraviolet (UV)-induced genetic damage caused by sunlight exposure, but which mutations drive this cancer? None have been conclusively tied to melanoma. The sheer abundance of these passenger mutations has obscured the search for genetic driver mutations that actually matter in melanoma development and progression.

20 Jul 2012

BioAlliance Pharma, Vestiq enter license agreement for Oravig to treat oropharyngeal candidiasis

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces it has signed a binding term sheet with Vestiq for the commercialization rights in the United States of Oravig (known as Loramyc in Europe) for the treatment of oropharyngeal candidiasis in adults.

20 Jul 2012

NCCN Guidelines for Patients: Lung Cancer Screening now available free of charge

The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation and Lung Cancer Alliance, announces the latest addition to the library of NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

19 Jul 2012

Tips to help minimize risks associated with acid reflux disease

While the overall death rates from several cancers such as breast and lung have gone down, there has been a meteoric rise in cases of esophageal cancer. Studies have shown that from 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from four to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer.

17 Jul 2012

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

17 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Identification of IL-9 antitumor activity in melanoma

High expression of interleukin -9 in immune cells inhibits growth of melanoma, show study findings suggesting a role for this T-cell cytokine in tumor suppression.

13 Jul 2012

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).

11 Jul 2012

Caffeine combats skin cancer risk

Drinking three or more cups of caffeinated coffee a day can significantly reduce a person’s risk for basal cell carcinoma, show study findings.

10 Jul 2012

Sox10 gene plays a central role in melanoma

Black skin cancer, also known as melanoma, is particularly aggressive and becoming increasingly common in Switzerland. Despite intensive research, however, there is still no treatment. Researchers from the University of Zurich have now discovered a gene that plays a central role in black skin cancer. Suppressing this gene in mice inhibits the development of melanoma and its proliferation - a discovery that could pave the way for new forms of therapy.

10 Jul 2012

Merck, PDS Biotechnology enter licensing agreement for Versamune

PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development.

9 Jul 2012

High expression of interleukin-9 in immune cells inhibits melanoma growth

Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.

9 Jul 2012

Cancer Therapeutics announces validation and performance of CTx-294886 plus Avastin

5 Jul 2012

Neighboring non-cancer cells may contribute to drug resistance

One of cancer's most frightening characteristics is its ability to return after treatment. In the case of many forms of cancer, including the skin cancer known as melanoma, tailored drugs can eradicate cancer cells in the lab, but often produce only partial, temporary responses in patients. One of the burning questions in the field of cancer research has been and remains: how does cancer evade drug treatment?

5 Jul 2012

Cancer Therapeutics reveals proof of concept for second development drug

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.

4 Jul 2012